Guggenheim on Immunovant (IMVT): 'we believe Graves' represents an underappreciated blockbuster commercial opp'y'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $44.00 price target on Immunovant (NASDAQ: IMVT).The analyst comments "Key Message ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
